Post by
Breakthorough1 on Jul 27, 2023 1:54pm
March 16 2023 (B)
"The first answer of the question with respect to supply of what we’re now considering is going to be commercial product. We’re very well evolved. We actually switched our CDMO in the 2022 horizon to make sure that we were well set for commercial supply, understanding that the ovarian study, whilst staged is, in effect, designed as being registrational. So as we are thinking about building out supply for the clinical studies today, but then the extension trials that will be registrational, we’re in a very good position with respect to the supply of commercial product."